Sphere Fluidics has rebranded to Sphere Bio reflecting its transition from a droplet-based microfluidics innovator to a commercial provider of integrated life sciences tools and solutions.

The new Sphere Bio brand aligns with the Company’s updated identity and strategic vision. Following significant operational scale-up and commercial growth over the past two years, including a change in leadership, the rebrand represents expanded market focus and growth potential in impactful and emerging research areas. These developments have been driven by global demand for Sphere Bio’s portfolio of solutions for single-cell analysis and isolation, including the Cyto-Mine platform and recently launched next-generation Cyto-Mine Chroma platform, alongside new assays to support an increasing range of biotherapeutic applications.

The rebrand also underscores the evolution of Sphere Bio’s capabilities beyond its foundation in engineering into comprehensive solutions that address complex industry challenges. Leveraging the Company’s proprietary picodroplet technology, its portfolio of tools and solutions are developed to maximize the efficiency and precision of single-cell functional analysis workflows, enabling project timelines to be reduced from months to weeks, facilitating leading and cost-effective life science research.

Dale Levitzke, CEO, Sphere Bio, commented: “Relaunching as Sphere Bio sets the stage for a transformative 2025 – it better represents us as a provider of integrated life sciences tools and solutions, while maintaining a strong basis in engineering. The new name maintains our strong brand recognition, reflecting the growth of the Company and its forward-looking approach, paving the way for an exciting future for our team and stakeholders.”